News | January 06, 2026
Abbott unveils Libre Assist to help meal management in diabetics
Abbott’s latest innovation promises to shift diabetes management from reactive to proactive
Abbott’s latest innovation promises to shift diabetes management from reactive to proactive
The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
India’s traditional medicine systems have also earned formal recognition in key bilateral trade agreements
He noted the enduring relevance of Siddha medicine as “a comprehensive, preventive and sustainable healthcare system in the contemporary world
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
The approval is supported by data from three pivotal clinical trials
Dr. Chand held several leadership positions within AstraZeneca and the broader biopharmaceutical industry
Dr. Bandichhor brings nearly two decades of experience from Dr. Reddy's Laboratories
Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
Subscribe To Our Newsletter & Stay Updated
